SEPN at a glance
Septerna, Inc. (SEPN, SEC CIK 1984086) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Septerna, Inc. (SEPN) reported revenue of $46.0 million (up 4174.5% from FY2024) and a net loss of $48.9 million. Diluted EPS was -$1.10.
- As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Septerna, Inc. (SEPN) shares worth $349.0 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Labrucherie Gil M on November 16, 2026 of 3,485 shares at $41.99 per share.
- In the last 90 days, SEPN insiders reported 0 open-market purchases ($0) and 18 open-market sales ($5.8M) on Form 4, a net sale of $5.8M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $46.0M
- +4174.5% vs prior year
- Insiders · 90 days
- 0 buys · 18 sells
- Net −$5.8M
- 13F holders
- 25 funds
- $349.0M · +0 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $18.9M, down $2.6M YoY from $21.5M, including $13.2M cumulative catch-up reduction
- Net loss $26.6M vs $8.2M net income YoY, operating loss $27.2M vs $2.6M income
- R&D spending $36.6M, up $12.3M YoY, led by other discovery/preclinical programs at $7.2M
- Cash, equivalents and marketable securities $565.2M, funding operations into mid-2029
- ATM proceeds $61.0M; operating cash use $61.6M through nine months, SEP-479 data expected first quarter 2027
Risk Factors
- Newly added development risk: SEP-204 selected as a development candidate in November 2026, expanding preclinical execution demands
- Regulatory risk: June 2026 FDA draft guidance permits one pivotal trial with confirmatory evidence, but FDA may still require a second trial
- Clinical safety risk: SEP-786 discontinued after two unanticipated Grade 3 elevated unconjugated bilirubin events
- Financial risk: $565.2 million in cash, equivalents and marketable securities expected to fund operations into mid-2029
- Trade and supply-chain risk: BIOSECURE Act restrictions could disrupt reliance on China-based CDMOs, including WuXi
AI summary of the SEPN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results and business highlights announced for the quarter ended September 30, 2026
- Detailed financial figures and operating updates available in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q3 2026 revenue $18.9M, including $5.2M milestone revenue and $11.0M Novo research services
- Net loss $26.6M versus $8.2M net income, reflecting higher R&D expense of $36.6M
Item 7.01: Regulation FD Disclosure
- SEP-204 selected as development candidate for Graves’ disease and thyroid eye disease
- Preclinical SEP-204 data reported at the 2026 American Thyroid Association Annual Meeting
Item EX-99.1: Item EX-99.1
- SEP-204 selected as potential first-in-class oral TSHR NAM for Graves’ disease and thyroid eye disease
- Preclinical models showed normalized T4, reduced thyroid enlargement and reduced orbital proptosis
Item EX-99.2: Item EX-99.2
- SEP-479 Phase 1 SAD/MAD data anticipated Q1 2027, with observed 3-4 day half-life supporting once-daily dosing
- SEP-204 Phase 1 initiation anticipated Q1 2027 for Graves’ disease and thyroid eye disease
Item 8.01: Other Events
- Rajiv Patni, M.D. appointed Chief Medical Officer effective August 24, 2026
- Senior leadership addition relevant to Septerna’s clinical-development strategy and medical oversight
Item 7.01: Regulation FD Disclosure
- Septerna appointed Rajiv Patni, M.D., an industry veteran, as Chief Medical Officer
- Leadership change adds senior clinical development expertise, potentially supporting pipeline advancement and regulatory execution
AI summaries of SEPN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SEPN
Don't miss the next SEPN filing
- Alerts as it files. A push when SEPN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SEPN, by share count.
- Ask anything. An AI agent that reads every SEPN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Labrucherie Gil M | Sell | Nov 16, 2026 | 3,485 | $41.99 |
| Labrucherie Gil M | Sell | Nov 16, 2026 | 15,815 | $41.48 |
| Labrucherie Gil M | Sell | Nov 16, 2026 | 700 | $43.00 |
| Finer Jeffrey | Sell | Nov 12, 2026 | 5,600 | $42.09 |
| Finer Jeffrey | Sell | Nov 12, 2026 | 1,977 | $46.16 |
| Finer Jeffrey | M | Nov 12, 2026 | 18,500 | $2.76 |
| Finer Jeffrey | Sell | Nov 12, 2026 | 2,800 | $44.23 |
| Finer Jeffrey | Sell | Nov 12, 2026 | 5,300 | $43.10 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $151K | $1.1M | $46.0M |
| Operating Income | - | -$80.8M | -$68.3M |
| Net Income | - | -$71.8M | -$48.9M |
| Op. Margin | - | -7518.4% | -148.6% |
| Net Margin | - | -6678.9% | -106.4% |
| Balance Sheet | |||
| Total Assets | $130.9M | $456.6M | $596.2M |
| Equity | -$38.4M | $420.0M | $381.9M |
| ROE | - | -17.1% | -12.8% |
| Per Share | |||
| EPS | $0.29 | $-7.26 | $-1.10 |
| Cash Flow | |||
| Operating CF | - | -$67.5M | $110.2M |
| CapEx | - | $2.1M | $518K |
Source: XBRL data in Septerna, Inc. (SEPN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate SEPN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 25 | $349.0M |
| Q2 2026 | 25 | $275.0M |
| Q1 2026 | 21 | $182.6M |
| Q4 2025 | 21 | $209.7M |
| Q3 2025 | 19 | $111.4M |
| Q2 2025 | 19 | $56.1M |
| Q1 2025 | 15 | $21.5M |
| Q4 2024 | 12 | $66.7M |
- D.E. Shaw & Co+186.7K (+402%)
- State Street Corp+145.5K (+22%)
- BlackRock+142.5K (+7%)
- Vanguard Capital Management LLC+132.6K (+11%)
- Morgan Stanley+72.6K (+54%)
- Two Sigma Investments−108.1K (-49%)
- Goldman Sachs Group−44.3K (-1%)
- Wells Fargo & Co−13.7K (-70%)
- Franklin Resources−12.3K (-66%)
- Millennium Management−7.5K (-15%)
- Ameriprise Financial+152.2K
- Prudential Financial+5.8K
- Renaissance Technologies LLC−41.4K
- FMR LLC (Fidelity)−23.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 157 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SEPN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 4 | Oct 19, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 8-K | Aug 25, 2026 | - | Analysis | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 4 | Aug 5, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
SEPN SEC filings: frequently asked questions
Are SEPN insiders buying or selling?
In the last 90 days, Septerna, Inc. (SEPN) officers, directors and 10% owners reported no open-market purchases and 18 open-market sales worth $5.8 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold SEPN stock?
As of September 30, 2026, the largest Septerna, Inc. (SEPN) holders among the 13F filers tracked by SignalX were Goldman Sachs Group ($118.1 million), BlackRock ($81.2 million), Vanguard Capital Management LLC ($53.0 million), State Street Corp ($31.2 million), Vanguard Portfolio Management LLC ($9.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SEPN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Septerna, Inc. (SEPN) reported revenue of $46.0 million (up 4174.5% from FY2024) and a net loss of $48.9 million. Diluted EPS was -$1.10. The figures come from the XBRL data in the 10-K.
What did SEPN report in its latest 8-K?
Septerna, Inc. (SEPN) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 results and business highlights announced for the quarter ended September 30, 2026.
What are the latest SEPN SEC filings?
Septerna, Inc. (SEPN) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 18, 2026.
What is SEPN's SEC CIK number?
Septerna, Inc. (SEPN)'s SEC Central Index Key (CIK) is 1984086. EDGAR lists every SEPN filing under that number.
Ask anything about SEPN
The research agent reads SEPN's filings, financials, insider trades and 13F holders, then answers with sources.